GI CANCERS

During a live event, Kashif Ali, MD, discussed outcomes from the NAPOLI 3 trial in terms of efficacy, tolerability, and dose modification.

A new triple therapy shows promising results for treating BRAF V600E-mutant metastatic colorectal cancer, significantly improving patient outcomes.

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use in patients with stage II colorectal cancer following surgery.

The FDA approves Agilent's MMR IHC Panel, enhancing personalized colorectal cancer treatment by identifying patients for targeted immunotherapy options.

During a live event, Kashif Ali, MD, reviewed the efficacy and safety of the NAPOLI 1 trial in patients with pancreatic cancer.

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising preclinical results.

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs of progress he has recently seen in this challenging disease setting.

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with FGF19 overexpression.

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite safety concerns.

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable HCC patients, as shown in the TALENTACE trial.

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal cancer, particularly if they had strong T-cell responses.

Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.

Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting lower efficacy and increased toxicity.

Akeso initiates a pivotal trial for cadonilimab and lenvatinib, targeting advanced liver cancer resistant to PD-1 therapy, addressing urgent treatment needs.

Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.

Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, enhancing response rates significantly.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting unmet clinical needs.

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining treatment standards.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic pancreatic cancer patients.

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.